RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

Newer formulations are even more effective at preventing illnesses that commonly afflict seniors — perhaps even dementia.

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

Foster carers will receive their first real increase in payments in 20 years, as the Minns government spends a record $1.2 ...

In advance of this week's CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The CDC used to have a vaccine advisory panel made of well-respected experts. This panel, ACIP, would meet to vote on which ...

Kennedy Jr. in the country's top health position, use of a long-approved vaccine against measles, mumps, rubella, and ...